Full-Time

Manager – Clinical Development

Prostate Specialty

Confirmed live in the last 24 hours

Axogen

Axogen

201-500 employees

Compensation Overview

$110.6k - $138.2k/yr

+ Bonus

Senior

Tampa, FL, USA

This position can be performed remotely but also has a physical office in Tampa, FL.

Category
Healthcare Administration & Support
Nursing & Allied Health Professionals
Medical, Clinical & Veterinary
Required Skills
Market Research
Product Management
Requirements
  • Bachelor’s degree in science, Engineering and/or in a related field.
  • Master’s in business administration or other advanced degree is strongly preferred.
  • Minimum of 5 years of demonstrated success and progressive experience in clinical, market development, or product management in the pharmaceutical, medical device, surgical implant, or biotech industry.
  • Experience in developing new clinical opportunities with paradigm-changing technologies preferred.
  • Understand and influence the key stakeholders’ drivers for change - patient, surgeons, site of care, and provider
  • Able to assess the strategic drivers to influence a market and skilled at building data-driven market models to value the clinical opportunity and costs to frame strategic recommendations
  • Ability to segment the market considering the surgeon, the referring physician, and the patient type, identify and resolve drivers and barriers to adoption for each.
  • Technical and clinical experience. Understand and shape the technical nuances to build the appropriate clinical data for both clinical adoption and reimbursement.
  • Experience understanding and working with care pathways and patient flow
  • Demonstrated experience moving from innovators and early adopters across the chasm to the early majority. Clear understanding of the drivers of the different segments of adopters
  • Able to make decisions in the face of imperfect data and create performance measures to “course correct” as the market moves
  • Able to enroll others in a vision and strategic plan, influence and effectively implement
  • Proven track record of building and maintaining Key Opinion Leader relationships
  • Orientation towards delivering on goals and being part of a fast-moving, collaborative team
  • Ability to manage multiple priorities in a fast-paced environment • Ability to collaborate, influence, and work with others in a dynamic, matrix environment
  • Must demonstrate strong interpersonal and communication skills with various levels of management and demonstrate the ability to manage differences and needs between multiple stakeholders
  • Willing and able to travel domestically, up to 75% of the time to respond to the needs of the customers and organization, some international travel is expected.
Responsibilities
  • Becomes an owner and internal advocate for Axogen’s New Clinical Development initiatives
  • Collaborate with market development and product marketing to Evaluate and determine market opportunities for Axogen products, Identify primary clinical value propositions
  • Manage team of KOL partners (robotic-assisted radical prostatectomy surgeons, society leadership, patient advocacy groups, etc.,)
  • Support and deliver new market value proposition to clinicians and KOLs and share gained insights from field-experience with Axogen
  • Support and organize medical and advisory board and sessions
  • Recruit and support innovators and early adopters in evaluating new clinical applications
  • Provide on-site training and assistance, solicit feedback and evaluate clinical value propositions, provide insights from product performance observations and suggestions to medical affairs, product management, and R&D
  • Lead regional early adoption programs and feedback initiatives, stay current on clinical research and developments as well as literature related to Axogen products. Provide critical analysis and summary as needed.
  • Conducts market research to assess, define and measure progress in new key clinical development segments
  • Supports the development of practice or technique guidelines in a procedure towards a standard of care with support from societies.
  • Creates market differentiation which establishes barriers to “me too” followers in the market.
  • Develops and communicates a compelling strategy by understanding of the customer, channel and competitive environment.
  • Communicates and collaborates to develop market segmentation, targeting, positioning, key messaging and competitive analysis within the development segment
  • Develops and collaborates on medical affairs communications including sales collateral creation, company website content, conference and educational events
  • Partners with sales leadership to understand market feedback and field training/messaging needs and deliver solutions
  • Works directly with thought leaders to assess the clinical and technology needs of the new segment or customer and the underlying broadly held assumptions
  • Drives the clinical development strategy and create framework and structure for future initiatives
  • Maintains relationships with key societies and oversees clinical conference presence, presentations, and stakeholder meetings
  • Demonstrates creative, insightful ideas and implements them quickly and effectively with nominal oversight
  • Evaluates and recommends markets/products for growth in peripheral nerve across the organization.
  • Creates and monitors clinical and business metrics to demonstrate effectiveness in technical growth and market penetration
  • Provides idea generation and creativity in this position, meets deadlines, manages and completes projects through commercialization, and develops techniques in the clinical sale of concepts and products.
  • Builds relationships with the key clinical influencers and identify potential opportunities for collaboration.
  • Builds and influences the economics of the procedure for all stakeholders.
  • Creates programs to lead change in the market, measure penetration into the potential market.
  • Identifies the key risk factors in the market and proactively addresses and reduces the risk.
Desired Qualifications
  • Experience in developing new clinical opportunities with paradigm-changing technologies preferred.

Company Size

201-500

Company Stage

IPO

Headquarters

Alachua, Florida

Founded

2002

Simplify Jobs

Simplify's Take

What believers are saying

  • The peripheral nerve repair market is projected to grow at a CAGR of 11.2% by 2030.
  • Increased focus on biologics drives innovation in Axogen's advanced grafts and tissue matrices.
  • AI integration in surgical planning offers potential enhancements in Axogen's product offerings.

What critics are saying

  • Leadership changes may disrupt ongoing projects or alter company focus.
  • Departure of experienced personnel could impact clinical research and development expertise.
  • Public offering of common stock may dilute existing shareholders' equity.

What makes Axogen unique

  • Axogen specializes in innovative surgical solutions for peripheral nerve injuries.
  • The company launched Avive+ Soft Tissue Matrix, a resorbable amniotic membrane allograft.
  • Axogen initiated a Biologics License Application for Avance Nerve Graft.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Paid Vacation

Paid Holidays

Employee Stock Purchase Plan

Tuition Reimbursement

Paid Parental Leave

Paid Caregiver Leave

Basic Life Insurance

Supplemental Life Insurance

Disability Insurance

Company News

Market Wire News
Jan 10th, 2025
AXGN - Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ALACHUA, Fla. and TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) - Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Craig Swandal as Vice President of Operations.

Investor Brand Network
Nov 7th, 2024
BioMedNewsBreaks - Annovis Bio Inc. (NYSE: ANVS) Strengthens Clinical Research Team with Appointment of Senior Clinical Scientist

Dr. Peterson, an experienced clinical researcher with a background in both academic and industry roles, joins from Axogen, where he specialized in therapies for peripheral nerve repair.

MedTech Dive
Aug 9th, 2024
Axogen names ex-Abbott exec Michael Dale as CEO

Axogen names ex-abbott exec Michael Dale as CEO.

GlobeNewswire
Jun 24th, 2024
Axogen, Inc Announces Full Launch Of Avive+ Soft Tissue Matrix(Tm)

ALACHUA, Fla. and TAMPA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the launch of its newest product, Avive+ Soft Tissue Matrix™. Avive+™ is intended for use as a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. Avive+ is processed and distributed in accordance with U.S. Food and Drug Administration (FDA) requirements for Human Cellular and Tissue-based Products (HCT/P) under 21 CFR Part 1271 regulations, U.S

GlobeNewswire
May 16th, 2024
Axogen Inc. Initiates Rolling Submission Of Biologics License Application To U.S. Food And Drug Administration (Fda) For Avance Nerve Graft(R)

ALACHUA, Fla. and TAMPA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, is pleased to announce that it has initiated the rolling submission process with the U.S. Food and Drug Administration for a Biologics License Application (BLA) for licensure of Avance Nerve Graft® on May 15, 2024.“Today’s milestone represents a significant step in our regulatory transition of Avance Nerve Graft to a biologic,” said Karen Zaderej, chairman, CEO, and president of Axogen, Inc. “I am grateful to our Axogen team and their diligence as we work towards completing the rolling BLA submission process.”The initial submission to the U.S. FDA includes the complete non-clinical data package for the BLA